Ipsen S.A. (IPN.PA)

107,60 -0,80 (-0,74%) Al cierre: 05:35PM CEST

Ipsen S.A.

65, quai Georges Gorse
Boulogne-Billancourt 92100
France
33 1 58 33 50 00
https://www.ipsen.com

Sector(es): Healthcare
Sector: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 5325

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. David Loew	MD, CEO & Director	2,22M	N/A	1967
Mr. Aymeric Le Chatelier	Executive VP & CFO	731,25k	N/A	1969
Dr. Aidan Murphy Ph.D.	Executive VP and Head of Technical Operations	N/A	N/A	1966
Mr. Craig Marks	Vice-President of Investor Relations	N/A	N/A	N/A
Mr. Francois Garnier	Executive VP of Legal Affairs, General Counsel & Chief Business Ethics Officer	N/A	N/A	1962
Ms. Gwenan White	Executive VP and Head of Communications, Public Affairs & Sustainability	N/A	N/A	N/A
Mr. Regis Mulot	Executive VP & Chief Human Resources Officer	N/A	N/A	1966
Ms. Dominique Bery	Head of Nordics & Baltics	N/A	N/A	1971
Mr. Bartosz Bednarz D.D.S.	Executive VP and Head of Global Product & Portfolio Strategy	N/A	N/A	N/A
Mr. Philippe Lopes-Fernandes CBO	Executive VP & Chief Business Officer	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en EUR.

Descripción

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.

Gobierno corporativo

El ISS Governance QualityScore de Ipsen S.A., a día 1 de abril de 2024, es 7. Las puntuaciones base son Auditoría: 8; Tablero: 7; Derechos de los accionistas: 7; Compensación: 6.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.